Cyclophosphamide as second-line therapy in multiple sclerosis: Benefits and risks

Neurological Sciences

Volumn 30, Issue SUPPL. 2, 2009, Pages

  Rinaldi, Luciano ^a   Perini, P ^a   Calabrese, M ^a   Gallo, P ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Cyclophosphamide; Disability; Multiple sclerosis; Progression; Side effects

Indexed keywords

ACREOLEIN; ALLOPURINOL; ANTIEMETIC AGENT; BETA INTERFERON; CORTICOTROPIN; CYCLOPHOSPHAMIDE; HYDROCHLOROTHIAZIDE; NEUROLEPTIC AGENT; PHENOBARBITAL; UNCLASSIFIED DRUG; WARFARIN;

ALOPECIA; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYSTITIS; DISEASE DURATION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; MELANOMA; MONOTHERAPY; MULTIPLE SCLEROSIS; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; SHORT COURSE THERAPY; SHORT SURVEY; SIDE EFFECT; TREATMENT RESPONSE;

ALKYLATING AGENTS; CYCLOPHOSPHAMIDE; HUMANS; MULTIPLE SCLEROSIS; RISK ASSESSMENT;

EID: 74049157818     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-009-0145-4     Document Type: Short Survey

References (15)

1. HL Weiner JA Cohen 2002 Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects Mult Scler 8 2 142 154 10.1191/1352458502ms790oa 1:CAS:528:DC%2BD38Xjt1Chs7c%3D 11990872 (Pubitemid 34256752)
2. G Aimard PF Girard J Raveau 1966 Multiple sclerosis and the autoimmunization process. Treatment by antimitotics Lyon Med 215 6 345 352 1:STN:280:DyaF28%2FpslOisQ%3D%3D 5906182
3. PF Girard G Aimard H Pellet 1967 Immunodepressive therapy in neurology Presse Med 75 19 967 968 1:STN:280:DyaF2s7mtlehsQ%3D%3D 6025851
4. SL Hauser, et al. 1983 Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH N Engl J Med 308 4 173 180 1:STN:280:DyaL3s%2FovVyisA%3D%3D 6294517
5. HL Weiner, et al. 1993 Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group Neurology 43 5 910 918 1:STN:280:DyaK3s3mtFKisw%3D%3D 8388090
6. The Canadian Cooperative Multiple Sclerosis Study Group 1991 The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis Lancet 337 8739 441 446
7. WH Likosky, et al. 1991 Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study J Neurol Neurosurg Psychiatry 54 12 1055 1060 10.1136/jnnp.54.12.1055 1:STN:280:DyaK387kvVClsQ%3D%3D 1783915
8. MI Gobbini, et al. 1999 Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis J Neuroimmunol 99 1 142 149 10.1016/S0165-5728(99)00039-9 1:CAS:528:DyaK1MXmtlGqsb4%3D 10496187 (Pubitemid 29488579)
9. P Perini P Gallo 2003 Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis J Neurol 250 7 834 838 10.1007/s00415-003-1089-x 1:CAS:528:DC%2BD3sXnsVSlurw%3D 12883926 (Pubitemid 36898116)
10. P Perini, et al. 2006 Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study J Neurol 253 8 1034 1040 10.1007/s00415-006-0154-7 1:CAS:528:DC%2BD28Xht1ertr3M 16609811 (Pubitemid 44441128)
11. La Mantia L et al (2002) Cyclophosphamide for multiple sclerosis. Cochrane Database Syst Rev (4):CD002819
12. E Portaccio, et al. 2003 Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort Mult Scler 9 5 446 450 10.1191/1352458503ms926oa 1:CAS:528:DC%2BD3sXptV2ktbY%3D 14582767 (Pubitemid 37287721)
13. TJ Stillwell RC Benson Jr 1988 Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients Cancer 61 3 451 457 10.1002/1097-0142(19880201)61:3<451::AID-CNCR2820610308>3.0.CO;2-G 1:STN:280:DyaL1c7gvFahsw%3D%3D 3338015
14. C Talar-Williams, et al. 1996 Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis Ann Intern Med 124 5 477 484 1:STN:280:DyaK287mvF2ntw%3D%3D 8602705
15. CD Radis, et al. 1995 Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study Arthritis Rheum 38 8 1120 1127 10.1002/art.1780380815 1:CAS:528:DyaK2MXns1WisLY%3D 7639809